Pfizer has decided to play a part in the Human Vaccines Project, which seeks to develop vaccine protection for infectious diseases such as HIV, dengue fever and cancer.
“Over the last decade, we’ve seen unprecedented technological advances in our understanding of the biology of diseases -- and new tools in designing vaccines including therapeutic vaccines,” Kathrin Jansen, head of vaccines research and development at Pfizer, said. “Yet, the translation from preclinical to clinical vaccine research has often been hampered by a lack of understanding of the desired human immune responses required to obtain optimal vaccine protection. With our strong heritage of translating scientific findings into the development of medicines and vaccines, Pfizer is proud to contribute to the consortium’s research efforts.”
Public and private research groups are teaming up on the project. The groups seek to apply the latest in medical technologies and knowledge to fight infectious diseases.
“We look forward to Pfizer’s contribution to the Human Vaccines Project as we launch an unprecedented public-private partnership in human immunology discovery, to decipher the human immunome and principles of protective immunity, to usher in a new era in global disease prevention,” Wayne Koff, founder of the Human Vaccines Project, said. “The human immune system holds the key to preventing and controlling a broad spectrum of infectious diseases, cancers, autoimmune diseases and allergies. By bringing together leading vaccine researchers, institutions and biopharmaceutical companies -- and harnessing recent technological advances in molecular and cellular biology and bioinformatics -- the project may potentially enable accelerated development of vaccines and immunotherapies for some of the most devastating diseases of our time.”